Clinical Trial Update: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib with Locally Ablative Radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Status: TERMINATED